Dominari Holdings Inc.

NasdaqCM DOMH

Dominari Holdings Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -126.05%

Dominari Holdings Inc. EBIT Margin is -126.05% for the Trailing 12 Months (TTM) ending September 30, 2024, a 93.13% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Dominari Holdings Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -1,834.43%.
Dominari Holdings Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -92,677.78%, a -624.50% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: DOMH

Dominari Holdings Inc.

CEO	Mr. Anthony C. Hayes Esq.
IPO Date	March 18, 1980
Location	United States
Headquarters	One Rockefeller Plaza
Employees	26
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Key trends

Past 5 years